Tri Locum Partners LP reported 19 positions worth $813.22M for the quarter ended Jun 30, 2026, up 19.4% on the prior quarter. It opened 4 new positions, added to 9, trimmed 6 and exited 1. Its largest holding is Johnson & Johnson at 13.3% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| ELVN Enliven Therapeutics, Inc. | +866.7K | – | $43.99M | 5.41% |
| AXSM Axsome Therapeutics, Inc. | +157.2K | +253.1% | $38.48M | 6.6% |
| VRTX Vertex Pharmaceuticals Inc / Ma | +72.5K | +56.0% | $36.00M | 12.33% |
| RVMD Revolution Medicines, Inc. | +151.8K | – | $28.43M | 3.5% |
| LLY ELI LILLY & Co | +14.7K | +23.8% | $17.68M | 11.29% |
| CYTK Cytokinetics Inc | +194.0K | – | $16.53M | 2.03% |
| JAZZ Jazz Pharmaceuticals plc | +63.1K | +39.7% | $15.19M | 6.57% |
| ARGX Argenx Se | +9,961 | +31.5% | $9.24M | 4.75% |
| DXCM Dexcom Inc | +122.3K | +17.5% | $8.24M | 6.8% |
| BBNX Beta Bionics, Inc. | +493.3K | – | $7.73M | 0.951% |
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| TMO Thermo Fisher Scientific Inc. | -132.4K | -100.0% | $65.08M | Exited |
| ISRG Intuitive Surgical Inc | -105.3K | -68.7% | $41.86M | 2.35% |
| MDGL Madrigal Pharmaceuticals, Inc. | -35.0K | -33.9% | $18.80M | 4.51% |
| UTHR UNITED THERAPEUTICS Corp | -23.3K | -33.2% | $12.65M | 3.13% |
| DFTX Definium Therapeutics, Inc. | -206.6K | -55.9% | $9.72M | 0.943% |
| TEVA Teva Pharmaceutical Industries Ltd | -274.2K | -26.9% | $9.29M | 3.11% |
| DNTH Dianthus Therapeutics, Inc. | -24.8K | -17.1% | $2.42M | 1.45% |
| Holding | Shares Sold | Trade Value | Prior Weight |
|---|---|---|---|
| TMO Thermo Fisher Scientific Inc. | -132.4K | $65.08M | 9.56% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | JNJ Johnson & Johnson | Healthcare | 424.9K | $107.92M | 13.27% | +10.4K | +2.5% | Added | 0.02% |
| 2 | VRTX Vertex Pharmaceuticals Inc / Ma | Healthcare | 201.8K | $100.24M | 12.33% | +72.5K | +56.0% | Added | 0.08% |
| 3 | LLY ELI LILLY & Co | Healthcare | 76.5K | $91.79M | 11.29% | +14.7K | +23.8% | Added | 0.01% |
| 4 | ASND Ascendis Pharma A/S | Healthcare | 258.7K | $69.01M | 8.49% | +3,408 | +1.3% | Added | 0.43% |
| 5 | DXCM Dexcom Inc | Healthcare | 820.5K | $55.26M | 6.8% | +122.3K | +17.5% | Added | 0.21% |
| 6 | AXSM Axsome Therapeutics, Inc. | Healthcare | 219.3K | $53.68M | 6.6% | +157.2K | +253.1% | Added | 0.42% |
| 7 | JAZZ Jazz Pharmaceuticals plc | Healthcare | 221.7K | $53.43M | 6.57% | +63.1K | +39.7% | Added | 0.34% |
| 8 | ELVN Enliven Therapeutics, Inc. | Healthcare | 866.7K | $43.99M | 5.41% | +866.7K | – | New | 1.18% |
| 9 | ARGX Argenx Se | Healthcare | 41.6K | $38.59M | 4.75% | +9,961 | +31.5% | Added | 0.07% |
| 10 | MDGL Madrigal Pharmaceuticals, Inc. | Healthcare | 68.3K | $36.66M | 4.51% | -35.0K | -33.9% | Reduced | 0.23% |
| 11 | RVMD Revolution Medicines, Inc. | Healthcare | 151.8K | $28.43M | 3.5% | +151.8K | – | New | 0.07% |
| 12 | UTHR UNITED THERAPEUTICS Corp | Healthcare | 47.0K | $25.48M | 3.13% | -23.3K | -33.2% | Reduced | 0.11% |
| 13 | TEVA Teva Pharmaceutical Industries Ltd | Healthcare | 746.8K | $25.30M | 3.11% | -274.2K | -26.9% | Reduced | 0.06% |
| 14 | TARS Tarsus Pharmaceuticals, Inc. | Healthcare | 328.3K | $20.67M | 2.54% | +75.8K | +30.0% | Added | 0.76% |
| 15 | ISRG Intuitive Surgical Inc | Healthcare | 48.0K | $19.08M | 2.35% | -105.3K | -68.7% | Reduced | 0.01% |
Tip. Select a row to see that position’s full history at Tri Locum Partners.
As of its Q2 2026 13F filing, Tri Locum Partners LP’s five largest positions were Johnson & Johnson (JNJ) at 13.3%, Vertex Pharmaceuticals Inc / Ma (VRTX) at 12.3%, ELI LILLY & Co (LLY) at 11.3%, Ascendis Pharma A/S (ASND) at 8.5%, Dexcom Inc (DXCM) at 6.8% of the reported portfolio.
Tri Locum Partners LP reported a 13F portfolio worth $813.22M across 19 positions for Q2 2026. That is up 19.4% from the previous quarter.
Its largest purchases by value were Enliven Therapeutics, Inc. ($43.99M), Axsome Therapeutics, Inc. ($38.48M), Vertex Pharmaceuticals Inc / Ma ($36.00M). It opened 4 new positions.
Its largest sales by value were Thermo Fisher Scientific Inc. ($65.08M), Intuitive Surgical Inc ($41.86M), Madrigal Pharmaceuticals, Inc. ($18.80M). It exited 1 positions entirely.
From the Form 13F-HR reports Tri Locum Partners LP files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.